Avara Pharmaceutical Services has closed an agreement to purchase AstraZeneca’s secondary solid dosage, form-manufacturing, packaging and distribution facility located in Reims, France.
Aspen Global Incorporated (AGI) has entered an agreement to acquire all the remaining rights to AstraZeneca’s established anaesthetic treatments for an upfront consideration of $555m.
Merck has entered a global strategic oncology collaboration to jointly develop and commercialise AstraZeneca’s lynparza (olaparib) for the treatment of multiple cancer types.